IAG933 for Mesothelioma

Phase-Based Progress Estimates
Mesothelioma+8 More
IAG933 - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new drug to see if it is safe and effective in treating mesothelioma, tumors with NF2/LATS1/LATS2 mutations, and tumors with YAP/TAZ fusion.

Eligible Conditions
  • Mesothelioma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

3 Primary · 11 Secondary · Reporting Duration: 3 years

1 year
Accumulation ratio (Racc) (dose escalation only)
Half life (T1/2) (dose escalation only)
Incidence of dose limiting toxicities during the first treatment cycle (dose escalation only)
Minimum serum concentration (Cmin) (dose escalation only)
3 years
Area under the curve (AUC)
Disease control rate (DCR)
Duration of response (DOR)
Maximum serum concentration (Cmax)
Number of patients with adverse events and serious adverse events
Number of patients with dose interruptions and dose changes
Overall response rate (ORR)
Overall survival (OS) (dose expansion only)
Progression free survival (PFS)
Time to reach Cmax (Tmax)

Trial Safety

Safety Progress

1 of 3

Similar Trials

Trial Design

3 Treatment Groups

Group 2
1 of 3
Group 3
1 of 3
Group 1
1 of 3

Experimental Treatment

156 Total Participants · 3 Treatment Groups

Primary Treatment: IAG933 · No Placebo Group · Phase 1

Group 2
Experimental Group · 1 Intervention: IAG933 · Intervention Types: Drug
Group 3
Experimental Group · 1 Intervention: IAG933 · Intervention Types: Drug
Group 1
Experimental Group · 1 Intervention: IAG933 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 3 years

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,698 Previous Clinical Trials
3,524,068 Total Patients Enrolled
5 Trials studying Mesothelioma
269 Patients Enrolled for Mesothelioma

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are willing to undergo a new tumor biopsy at screening/baseline, and again during therapy on this study.
You must be at least 18 years of age to participate in this study.
You have mesothelioma, or you have a solid tumor of other types, or you have a primary brain tumor

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 6th, 2021

Last Reviewed: November 1st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.